Decio Armanini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5474596/publications.pdf

Version: 2024-02-01

179 papers	4,967 citations	101543 36 h-index	114465 63 g-index
179 all docs	179 docs citations	179 times ranked	4215 citing authors

#	Article	IF	Citations
1	Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2023, 23, 188-195.	1.2	2
2	Unilateral primary aldosteronism considerations about the diagnostic criteria, adrenalectomy, and short and long time biochemical and clinical evaluation. Journal of Clinical Hypertension, 2022, 24, 116-118.	2.0	1
3	Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. International Journal of Molecular Sciences, 2022, 23, 4110.	4.1	73
4	Can the treatment of polycystic ovary syndrome with spironolactone prevent severe COVID infection?. European Journal of Endocrinology, 2022, 186, L11-L13.	3.7	0
5	Primary aldosteronism: considerations about the evaluation of the aldosterone to renin ratio during canrenone treatment. Journal of Endocrinological Investigation, 2021, 44, 2009-2010.	3.3	0
6	Idiopathic inflammatory myopathies and hypertension: Possible involvement of hormonal factors. Journal of Clinical Hypertension, 2021, 23, 1567-1569.	2.0	1
7	A multidisciplinary approach to the management of adrenal incidentaloma. Expert Review of Endocrinology and Metabolism, 2021, 16, 201-212.	2.4	15
8	Endometriosis Susceptibility to Dapsone-Hydroxylamine-Induced Alterations Can Be Prevented by Licorice Intake: In Vivo and In Vitro Study. International Journal of Molecular Sciences, 2021, 22, 8476.	4.1	0
9	Primary aldosteronism: Involvement of sympathetic system in the persistence of hypertension after surgery. Journal of Clinical Hypertension, 2020, 22, 1616-1617.	2.0	1
10	Coronavirus-19: Possible Therapeutic Implications of Spironolactone and Dry Extract of Glycyrrhiza glabra L. (Licorice). Frontiers in Pharmacology, 2020, 11, 558418.	3.5	10
11	Plant natural products with anti-thyroid cancer activity. FÃ¬toterapÃ¬Ã¢, 2020, 146, 104640.	2.2	16
12	Human Sperm Capacitation Involves the Regulation of the Tyr-Phosphorylation Level of the Anion Exchanger 1 (AE1). International Journal of Molecular Sciences, 2020, 21, 4063.	4.1	9
13	Is sodium excretion a reliable marker of sodium intake?. Journal of Clinical Hypertension, 2020, 22, 306-306.	2.0	1
14	Licorice: From Pseudohyperaldosteronism to Therapeutic Uses. Frontiers in Endocrinology, 2019, 10, 484.	3.5	38
15	Evaluation and implications of salt intake and excretion. Journal of Clinical Hypertension, 2019, 21, 950-952.	2.0	3
16	Pitfalls in urinary sodium excretion. Journal of Clinical Hypertension, 2019, 21, 1635-1636.	2.0	3
17	Enigma of the Origin of Primary Aldosteronism. Hypertension, 2019, 74, 745-746.	2.7	4
18	Aldosterone in Gynecology and Its Involvement on the Risk of Hypertension in Pregnancy. Frontiers in Endocrinology, 2019, 10, 575.	3.5	16

#	Article	IF	Citations
19	Biological Effects of EF24, a Curcumin Derivative, Alone or Combined with Mitotane in Adrenocortical Tumor Cell Lines. Molecules, 2019, 24, 2202.	3.8	22
20	Is corifollitropin alfa effective in controlled ovarian stimulation among all poor ovarian responders? A retrospective comparative study. Gynecological Endocrinology, 2019, 35, 894-898.	1.7	4
21	Hypertension in pregnancy: Role of body mass index, insulin resistance, aldosterone, and calcium homeostasis. Journal of Clinical Hypertension, 2019, 21, 624-626.	2.0	2
22	Licorice and 11Î²-Hydroxysteroid Dehydrogenase. , 2019, , 644-651.		0
23	Proinflammatory/profibrotic effects of aldosterone in Gitelmanâ€™s syndrome, a human model opposite to hypertension. Journal of Endocrinological Investigation, 2019, 42, 521-526.	3.3	2
24	Crude extract of Origanum vulgare L. induced cell death and suppressed MAPK and PI3/Akt signaling pathways in SW13 and H295R cell lines. Natural Product Research, 2019, 33, 1646-1649.	1.8	19
25	Anticancer Effects of Wild Mountain Mentha longifolia Extract in Adrenocortical Tumor Cell Models. Frontiers in Pharmacology, 2019, 10, 1647.	3.5	14
26	The influence of thyroid autoimmunity on embryo quality in women undergoing assisted reproductive technology. Gynecological Endocrinology, 2018, 34, 752-755.	1.7	36
27	Uterine fibroids and risk of hypertension: Implication of inflammation and a possible role of the reninâ€angiotensinâ€aldosterone system. Journal of Clinical Hypertension, 2018, 20, 727-729.	2.0	10
28	Ameliorative effect of myo-inositol on red blood cell alterations in polycystic ovary syndrome: in vitro study. Gynecological Endocrinology, 2018, 34, 233-237.	1.7	3
29	Astaxanthin Prevents Human Papillomavirus L1 Protein Binding in Human Sperm Membranes. Marine Drugs, 2018, 16, 427.	4.6	12
30	Relationship between water and salt intake, osmolality, vasopressin, and aldosterone in the regulation of blood pressure. Journal of Clinical Hypertension, 2018, 20, 1455-1457.	2.0	7
31	Relationship between sodium, pentraxinâ€3 and aldosterone in inflammation and cardiovascular risk. Journal of Clinical Hypertension, 2018, 20, 932-934.	2.0	0
32	Evaluation of angiotensin <scp>II</scp> typeâ€1 receptor antibodies in primary aldosteronism and further considerations about their possible pathogenetic role. Journal of Clinical Hypertension, 2018, 20, 1313-1318.	2.0	15
33	Association of primary aldosteronism with chronic thyroiditis. Endocrine, 2017, 55, 303-306.	2.3	9
34	Role of adrenocorticotropic hormone in essential hypertension and primary aldosteronism. Journal of Clinical Hypertension, 2017, 19, 287-289.	2.0	3
35	Persistent amenorrhea and decreased DHEAS to cortisol ratio after recovery from anorexia nervosa. Gynecological Endocrinology, 2017, 33, 311-314.	1.7	6
36	Dapsone hydroxylamine-mediated alterations in human red blood cells from endometriotic patients. Gynecological Endocrinology, 2017, 33, 928-932.	1.7	2

#	Article	IF	Citations
37	Hypothesis on a relationship between hyperaldosteronism, inflammation, somatic mutations, and autoimmunity. Journal of Clinical Hypertension, 2017, 19, 1060-1062.	2.0	14
38	Sodium intake, sodium excretion, and cardiovascular risk: involvement of genetic, hormonal, and epigenetic factors. Journal of Clinical Hypertension, 2017, 19, 650-652.	2.0	6
39	In vitro effects of glycyrrhetinic acid and hyaluronic acid on the growth of vulvovaginal Candida albicans and other yeasts. Microbiologia Medica, 2017, 32, .	0.1	3
40	Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. Journal of Endocrinological Investigation, 2016, 39, 1015-1021.	3.3	16
41	Spironolactone in the treatment of polycystic ovary syndrome. Expert Opinion on Pharmacotherapy, 2016, 17, 1713-1715.	1.8	27
42	Interrelationship Between Vitamin D Insufficiency, Calcium Homeostasis, Hyperaldosteronism, and Autoimmunity. Journal of Clinical Hypertension, 2016, 18, 614-616.	2.0	8
43	Considerations for the Assessment of Salt Intake by Urinary Sodium Excretion in Hypertensive Patients. Journal of Clinical Hypertension, 2016, 18, 1143-1145.	2.0	13
44	Some Considerations About Primary Aldosteronism and Its Followâ€Up. Journal of Clinical Hypertension, 2016, 18, 1213-1215.	2.0	2
45	Syndromes that Mimic an Excess of Mineralocorticoids. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 231-235.	2.2	19
46	Mineralocorticoid receptor is involved in the aldosterone pathway in human red blood cells. American Journal of Translational Research (discontinued), 2016, 8, 314-28.	0.0	10
47	The story of spironolactones from 1957 to now: from sodium balance to inflammation. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Società Italiana Di Nefrologia, 2016, 33 Suppl 66, 33.S66.12.	0.3	9
48	Astaxanthin Improves Human Sperm Capacitation by Inducing Lyn Displacement and Activation. Marine Drugs, 2015, 13, 5533-5551.	4.6	32
49	Transient hypercortisolism and symptomatic hyperthyroidism associated to primary hyperparathyroidism in an elderly patient: case report and literature review. BMC Endocrine Disorders, 2015, 15, 4.	2.2	2
50	Maternal and Fetal Outcomes in Preeclampsia: Interrelations Between Insulin Resistance, Aldosterone, Metabolic Syndrome, and Polycystic Ovary Syndrome. Journal of Clinical Hypertension, 2015, 17, 783-785.	2.0	8
51	Heart Failure Due to Adrenergic Myocardial Toxicity From a Pheochromocytoma. Circulation: Heart Failure, 2015, 8, 646-648.	3.9	6
52	Menstrual cycle length: a surrogate measure of reproductive health capable of improving the accuracy of biochemical/sonographical ovarian reserve test in estimating the reproductive chances of women referred to ART. Reproductive Biology and Endocrinology, 2015, 13, 28.	3.3	27
53	Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs. Expert Opinion on Pharmacotherapy, 2014, 15, 909-912.	1.8	31
54	Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis. Reproductive BioMedicine Online, 2014, 28, 773-779.	2.4	22

#	Article	IF	Citations
55	Effect of various commercial buffers on sperm viability and capacitation. Systems Biology in Reproductive Medicine, 2014, 60, 239-244.	2.1	5
56	Human Red Blood Cells Alterations in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2494-2501.	3.6	19
57	High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 169, 248-251.	1.1	58
58	Microalbuminuria and Hypertension in Pregnancy: Role of Aldosterone and Inflammation. Journal of Clinical Hypertension, 2013, 15, 612-614.	2.0	8
59	Effect of Astaxanthin on Human Sperm Capacitation. Marine Drugs, 2013, 11, 1909-1919.	4.6	38
60	Resolution of hypertension and secondary aldosteronism after surgical treatment of primary hyperparathyroidism. Journal of Endocrinological Investigation, 2013, 36, 665-6.	3.3	3
61	Serum Potassium, Thiazides, Aldosterone, and Mineralocorticoid Receptors. Hypertension, 2012, 60, e9.	2.7	5
62	Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. European Journal of Endocrinology, 2012, 166, 703-710.	3.7	61
63	Salt and aldosterone do not get along with each other: implication of mineralocorticoid receptors in the profibrotic action of aldosterone. Kidney International, 2012, 81, 118.	5.2	2
64	Polycystic ovary syndrome: Implications of measurement of plasma aldosterone, renin activity and progesterone. Steroids, 2012, 77, 655-658.	1.8	36
65	Preeclampsia. Hypertension, 2012, 59, 1099-1100.	2.7	5
66	Authorsâ€™ Response: Anti-Helicobacter pylori antibodies, autoimmunity, aldosterone and infertility: causal or casual association with polycystic ovary syndrome?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2012, 163, 243-244.	1.1	0
67	Anti-Helicobacter pylori antibodies in cervical mucus: a new cause of infertility. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 155, 157-160.	1.1	29
68	Editorial Comment to Receptor dependent immobilization of spermatozoa by sperm immobilization factor isolated from Escherichia coli: Proof of evidence. International Journal of Urology, 2011, 18, 603-604.	1.0	1
69	Endogenous reactive oxygen species content and modulation of tyrosine phosphorylation during sperm capacitation. Journal of Developmental and Physical Disabilities, 2011, 34, 411-419.	3.6	36
70	Evaluation of correct endogenous reactive oxygen species content for human sperm capacitation and involvement of the NADPH oxidase system. Human Reproduction, 2011, 26, 3264-3273.	0.9	42
71	Choice of Diuretic Therapy and Reconsideration for Aldosterone Receptors Blockers. Hypertension, 2010, 55, e5.	2.7	7
72	Oxidative stress-related proteins in a Connâ€™s adenoma tissue. Relevance for aldosteroneâ€™s prooxidative and proinflammatory activity. Journal of Endocrinological Investigation, 2010, 33, 48-53.	3.3	21

#	Article	IF	Citations
73	Evaluation of erythrocyte band 3 phosphotyrosine level, glutathione content, CA-125, and human epididymal secretory protein E4 as combined parameters in endometriosis. Fertility and Sterility, 2010, 94, 1616-1621.	1.0	34
74	Licorice. , 2010, , 479-486.		1
75	Identification of the 11â€‰Î²-hydroxysteroid Dehydrogenase Type 1 mRNA and Protein in Human Mononuclear Leukocytes. Experimental and Clinical Endocrinology and Diabetes, 2009, 117, 514-518.	1.2	4
76	In vitro effects of glycyrrhetinic acid on the growth of clinical isolates of Candida albicans. Phytotherapy Research, 2009, 23, 572-574.	5.8	35
77	Effect of canrenone and amiloride on the prooxidative effect induced by aldosterone in human mononuclear leukocytes in vitro. Journal of Endocrinological Investigation, 2009, 32, 895-898.	3.3	4
78	Some considerations about evolution of idiopathic primary aldosteronism. Journal of Endocrinological Investigation, 2009, 32, 623-625.	3.3	7
79	Antiviral effects of Glycyrrhiza species. Phytotherapy Research, 2008, 22, 141-148.	5.8	392
80	Effect of glycyrrhetinic acid on membrane band 3 in human erythrocytes. Archives of Biochemistry and Biophysics, 2008, 479, 46-51.	3.0	13
81	Genital tract infections and infertility. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 140, 3-11.	1.1	262
82	Glycyrrhetinic acid as inhibitor or amplifier of permeability transition in rat heart mitochondria. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 313-323.	2.6	19
83	A hypothesis on the death of the Greek philosopher Heraclitus. Journal of Endocrinological Investigation, 2008, 31, 742-743.	3.3	2
84	Polycystic Ovary Syndrome: Implications of Corticotropin in the Regulation of Blood Pressure, Aldosterone, and Androgen Secretion. Hypertension, 2007, 50, e24; author reply e25.	2.7	2
85	Spontaneous Resolution of Idiopathic Aldosteronism After Long-Term Treatment With Potassium Canrenoate. Hypertension, 2007, 50, e69-70.	2.7	24
86	Treatment of polycystic ovary syndrome with spironolactone plus licorice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 131, 61-67.	1.1	61
87	The expression of the human steroid sulfatase-encoding gene is driven by alternative first exons. Journal of Steroid Biochemistry and Molecular Biology, 2007, 107, 22-29.	2.5	20
88	Antialdosteronici vecchi e nuovi nel trattamento dellâ€™ipertensione e dello scompenso cardiaco. L Endocrinologo, 2007, 8, 177-183.	0.0	0
89	Aldosterone and thrombosis formation: Implications for ischemic and atherosclerotic heart disease. Journal of Endocrinological Investigation, 2006, 29, 675-676.	3.3	4
90	Effect of licorice on PTH levels in healthy women. Steroids, 2006, 71, 403-408.	1.8	23

#	Article	IF	Citations
91	Identification of the mineralocorticoid receptor in human spermatozoa. International Journal of Molecular Medicine, 2006, 18, 649.	4.0	1
92	Mononuclear Leukocyte Mineralocorticoid Receptors. Hypertension, 2006, 47, e4; author reply e4-5.	2.7	5
93	Aldosterone-mediated endothelial remodeling and oxidative stress. Kidney International, 2005, 68, 1899.	5.2	2
94	Long-Term Results of Adrenalectomy in Patients with Aldosterone-Producing Adenomas: Multivariate Analysis of Factors Affecting Unresolved Hypertension and Review of the Literature. American Surgeon, 2005, 71, 864-869.	0.8	121
95	Aldosterone, Inflammation, and Preeclampsia. Hypertension, 2005, 45, e10.	2.7	4
96	Carbenoxolone Induces Oxidative Stress in Liver Mitochondria, Which Is Responsible for Transition Pore Opening. Endocrinology, 2005, 146, 2306-2312.	2.8	30
97	Idiopathic primary hyperaldosteronism: Normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate. Journal of Endocrinological Investigation, 2005, 28, 236-240.	3.3	16
98	Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile. Journal of Endocrinological Investigation, 2005, 28, 49-53.	3.3	88
99	A history of the therapeutic use of liquorice in Europe. Journal of Ethnopharmacology, 2005, 99, 317-324.	4.1	310
100	Glycyrrhetinic acid, the active principle of licorice, can reduce the thickness of subcutaneous thigh fat through topical application. Steroids, 2005, 70, 538-542.	1.8	53
101	Oxidative stress and profibrotic action of aldosterone. American Journal of Hypertension, 2005, 18, 441-441.	2.0	0
102	Aldosterone-mediated endothelial remodeling and oxidative stress. Kidney International, 2005, 68, 1899-1899.	5.2	0
103	Effect of Aldosterone and Glycyrrhetinic Acid on the Protein Expression of PAI-1 and p22phox in Human Mononuclear Leukocytes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1973-1976.	3.6	110
104	A Particular Phenotype in a Girl with Aldosterone Synthase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3168-3172.	3.6	8
105	On the mechanism of mitochondrial permeability transition induction by glycyrrhetinic acid. Biochimica Et Biophysica Acta - Bioenergetics, 2004, 1658, 195-201.	1.0	59
106	Licorice reduces serum testosterone in healthy women. Steroids, 2004, 69, 763-766.	1.8	84
107	Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism. Molecular and Cellular Endocrinology, 2004, 217, 119-125.	3.2	61
108	Alzheimer's Disease: Pathophysiological Implications of Measurement of Plasma Cortisol, Plasma Dehydroepiandrosterone Sulfate, and Lymphocytic Corticosteroid Receptors. Endocrine, 2003, 22, 113-118.	2.2	39

#	Article	IF	Citations
109	High Prevalence of Thyroid Ultrasonographic Abnormalities in Primary Aldosteronism. Endocrine, 2003, 22, 155-160.	2.2	10
110	Glycyrrhetinic acid-induced permeability transition in rat liver mitochondria. Biochemical Pharmacology, 2003, 66, 2375-2379.	4.4	62
111	Grapefruit juice inhibits 11Î²-hydroxysteroid dehydrogenase in vivo , in man. Clinical Endocrinology, 2003, 59, 143-144.	2.4	14
112	Effect of licorice on the reduction of body fat mass in healthy subjects. Journal of Endocrinological Investigation, 2003, 26, 646-650.	3.3	54
113	Pseudohyperaldosteronism: Pathogenetic Mechanisms. Critical Reviews in Clinical Laboratory Sciences, 2003, 40, 295-335.	6.1	27
114	Unilateral Adrenal Tumor, Erectile Dysfunction and Infertility in a Patient with 21-Hydroxylase Deficiency: Effects of Glucocorticoid Treatment and Surgery. Experimental and Clinical Endocrinology and Diabetes, 2003, 111, 41-43.	1.2	12
115	Licorice Consumption and Serum Testosterone in Healthy Man. Experimental and Clinical Endocrinology and Diabetes, 2003, 111, 341-343.	1.2	32
116	Different Inactivating Mutations of the Mineralocorticoid Receptor in Fourteen Families Affected by Type I Pseudohypoaldosteronism. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2508-2517.	3.6	81
117	Growth hormone and insulin-like growth factor I in a Sydney Olympic gold medallist. British Journal of Sports Medicine, 2002, 36, 148-149.	6.7	12
118	History of The Endocrine Effects of Licorice. Experimental and Clinical Endocrinology and Diabetes, 2002, 110, 257-261.	1.2	148
119	Furosemide and 11Î²-hydroxysteroid dehydrogenase activity, in man. Experimental and Clinical Endocrinology and Diabetes, 2002, 110, 272-276.	1.2	8
120	Reduction of Serum Testosterone in Men by Licorice. New England Journal of Medicine, 1999, 341, 1158-1158.	27.0	73
121	Transient pseudo-hypoaldosteronism following resection of the ileum: Normal level of lymphocytic aldosterone receptors outside the acute phase. Journal of Endocrinological Investigation, 1999, 22, 122-127.	3.3	25
122	Regulation of corticosteroid receptors in patients with anorexia nervosa and Cushing's syndrome. Journal of Endocrinology, 1998, 158, 435-439.	2.6	14
123	Corticosteroid receptors in mononuclear leucocytes of obese subjects. Journal of Endocrinology, 1998, 156, 187-194.	2.6	8
124	Hypertensive cardiomegaly caused by an aldosterone-secreting adenoma in a newborn. Journal of Endocrinological Investigation, 1997, 20, 86-89.	3.3	15
125	Dexamethasone suppression test: Corticosteroid receptors regulation in mononuclear leukocytes of young and aged subjects. Aging Clinical and Experimental Research, 1996, 8, 360-364.	2.9	6
126	Further studies on the mechanism of the mineralocorticoid action of licorice in humans. Journal of Endocrinological Investigation, 1996, 19, 624-629.	3.3	59

#	Article	IF	Citations
127	Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior. Fertility and Sterility, 1995, 64, 511-517.	1.0	72
128	Pseudohypoaldosteronism: Evaluation of type I receptors by radioreceptor assay and by antireceptor antibodies. Steroids, 1995, 60, 161-163.	1.8	5
129	Long-term treatment of mineralocorticoid excess syndromes. Steroids, 1995, 60, 81-86.	1.8	45
130	Molecular characterization of the mineralocorticoid receptor in pseudohypoaldosteronism. Steroids, 1995, 60, 164-167.	1.8	12
131	Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism.. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1115-1121.	3.6	56
132	No alteration in the primary structure of the mineralocorticoid receptor in a family with pseudohypoaldosteronism.. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 32-38.	3.6	57
133	Immunofluorescence of mineralocorticoid receptors in peripheral lymphocytes: Presence of receptor-like activity in patients with the autosomal dominant form of pseudohypoaldosteronism, and its absence in the recessive form. Journal of Steroid Biochemistry and Molecular Biology, 1994, 51, 267-273.	2.5	13
134	The enigma of pseudohypoaldosteronism. Steroids, 1994, 59, 96-99.	1.8	9
135	Androgen binding sites in peripheral human mononuclear leukocytes of healthy males and females. Journal of Steroid Biochemistry and Molecular Biology, 1994, 48, 403-408.	2.5	14
136	Corticosteroid receptors in lymphocytes: a possible marker of brain involution?. Journal of Steroid Biochemistry and Molecular Biology, 1994, 49, 429-434.	2.5	14
137	Juxtaglomerular Cell Tumor of the Kidney. Clinical and Experimental Hypertension, 1994, 16, 41-53.	1.3	13
138	Regulation of aldosterone receptors in hypertension. Steroids, 1993, 58, 611-613.	1.8	9
139	Corticosteroid receptors and aging. Journal of Steroid Biochemistry and Molecular Biology, 1993, 45, 191-194.	2.5	17
140	Transient Pseudohypoaldosteronism in Obstructive Renal Disease with Transient Reduction of Lymphocytic Aldosterone Receptors. Hormone Research, 1993, 39, 152-155.	1.8	36
141	Mineralocorticoid effector mechanism in preeclampsia. Journal of Clinical Endocrinology and Metabolism, 1992, 74, 946-9.	3.6	21
142	Concomitant Release of Renin, Angiotensin I, and Angiotensin II During Supervision of Human Juxtaglomerular Cell Tumor. American Journal of Hypertension, 1992, 5, 566-569.	2.0	4
143	Metabolic effects of lisinopril versus hydrochlorothiazide plus amiloride in essential hypertension. Current Therapeutic Research, 1992, 52, 397-405.	1.2	3
144	Corticosteroid receptors and lymphocyte subsets in mononuclear leukocytes in aging. American Journal of Physiology - Endocrinology and Metabolism, 1992, 262, E464-E466.	3.5	14

#	Article	IF	Citations
145	Mineralocorticoid effector mechanism in preeclampsia. Journal of Clinical Endocrinology and Metabolism, 1992, 74, 946-949.	3.6	11
146	Steroids and hypertension. Journal of Steroid Biochemistry and Molecular Biology, 1991, 40, 35-44.	2.5	17
147	Pseudohypoaldosteronism and mineralocorticoid receptor abnormalities. Journal of Steroid Biochemistry and Molecular Biology, 1991, 40, 363-365.	2.5	18
148	Effects of licorice on urinary metabolites of Cortisol and cortisone. Journal of Hypertension, 1991, 9, S276.	0.5	2
149	Effects of licorice on urinary metabolites of cortisol and cortisone. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 1991, 9, S274-5.	0.1	2
150	New Aspects of Mineralocorticoid Hypertension. Hormone Research, 1990, 34, 175-180.	1.8	12
151	Pseudohypoaldosteronism in Eight Families: Different Forms of Inheritance Are Evidence for Various Genetic Defects. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 638-641.	3.6	61
152	Pseudohyperaldosteronism from liquorice-containing laxatives. Journal of Endocrinological Investigation, 1990, 13, 847-848.	3.3	20
153	Volume regulation of human lymphocytes by aldosterone in isotonic media. American Journal of Physiology - Endocrinology and Metabolism, 1989, 257, E170-E174.	3.5	30
154	Mineralocorticoid effector mechanism of liquorice derivatives in human mononuclear leukocytes. Journal of Endocrinological Investigation, 1989, 12, 303-306.	3.3	22
155	The pathogenesis of pseudohyperaldosteronism from carbenoxolone. Journal of Endocrinological Investigation, 1989, 12, 337-341.	3.3	18
156	Canrenone and Androgen Receptor-Active Materials in Plasma of Cirrhotic Patients during Long-Term K-Canrenoate or Spironolactone Therapy. Digestion, 1989, 44, 155-162.	2.3	12
157	LACK OF EFFECT OF ALDOSTERONE ON INTRACELLULAR SODIUM AND POTASSIUM IN MONONUCLEAR LEUCOCYTES FROM PATIENTS WITH PSEUDOHYPOALDOSTERONISM. Clinical Endocrinology, 1988, 28, 67-74.	2.4	21
158	Parallel determination of mineralocorticoid and glucocorticoid receptors in T- and B-lymphocytes of human spleen. European Journal of Endocrinology, 1988, 118, 479-482.	3.7	34
159	Aldosterone Receptors in Different Types of Primary Hyperaldosteronism*. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 101-104.	3.6	48
160	Mineralocorticoid effector mechanism in human mononuclear leukocytes. The Journal of Steroid Biochemistry, 1987, 27, 967-970.	1.1	7
161	Effect of aldosterone on sodium and potassium concentrations in human mononuclear leukocytes. American Journal of Physiology - Endocrinology and Metabolism, 1987, 252, E505-E508.	3.5	28
162	Dexamethasone-suppressible hyperaldosteronism: Pathophysiology, clinical aspects, and new insights into the pathogenesis. Klinische Wochenschrift, 1987, 65, 437-444.	0.6	12

#	Article	IF	Citations
163	The Determination of Mineralocorticoid Receptors in Human Mononuclear Leukocytes from Patients with Mineralocorticoid Excess: Physiological and Pathological Implications. Clinical and Experimental Hypertension, 1986, 8, 781-785.	0.3	2
164	Plasma mineralocorticoid activity, mineralocorticoid receptors and intracellular electrolytes in patients with dexamethasone-suppressible hyperaldosteronism (DSH). European Journal of Endocrinology, 1986, 113, S179-S180.	3.7	2
165	A NEW FAMILY WITH DEXAMETHASONEâ€SUPPRESSIBLE HYPERALDOSTERONISM: ALDOSTERONE UNRESPONSIVENESS TO ANGIOTENSIN II. Clinical Endocrinology, 1985, 22, 777-785.	2.4	39
166	IN-VIVO METABOLITES OF SPIRONOLACTONE AND POTASSIUM CANRENOATE: DETERMINATION OF POTENTIAL ANTI-ANDROGENIC ACTIVITY BY A MOUSE KIDNEY CYTOSOL RECEPTOR ASSAY. Clinical Endocrinology, 1985, 23, 341-347.	2.4	27
167	Characterization of aldosterone binding sites in circulating human mononuclear leukocytes. American Journal of Physiology - Endocrinology and Metabolism, 1985, 248, E388-E390.	3.5	69
168	Aldosterone-Receptor Deficiency in Pseudohypoaldosteronism. New England Journal of Medicine, 1985, 313, 1178-1181.	27.0	118
169	Parallel determination of glucocorticoid receptors in human mononuclear and polymorphonuclear leukocytes after Percoll separation. Journal of Endocrinological Investigation, 1985, 8, 45-47.	3.3	18
170	Binding of agonists and antagonists to mineralocorticoid receptors in human peripheral mononuclear leucocytes. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 1985, 3, S157-9.	0.1	4
171	AFFINITY OF LIQUORICE DERIVATIVES FOR MINERALOCORTICOID AND GLUCOCORTICOID RECEPTORS. Clinical Endocrinology, 1983, 19, 609-612.	2.4	149
172	The Mechanism of Mineralocorticoid Action of Carbenoxolone*. Endocrinology, 1982, 111, 1683-1686.	2.8	54
173	Mineralocorticoid hypertension due to a nasal spray containing 9Î±-fluoroprednisolone. American Journal of Medicine, 1981, 71, 352-357.	1.5	36
174	Effect of Angiotensin II and Converting Enzyme Inhibitor (Captopril) on Blood Pressure, Plasma Renin Activity and Aldosterone in Primary Aldosteronism. Clinical Science, 1981, 61, 289s-293s.	0.0	44
175	Effect of Metoclopramide on Plasma Aldosterone in Normal Subjects, Primary Aldosteronism and Hypopituitarism. Hormone and Metabolic Research, 1981, 13, 464-467.	1.5	20
176	Plasma Renin Activity and Urinary Aldosterone in Cushing's Syndrome. Hormone and Metabolic Research, 1978, 10, 65-71.	1.5	25
177	Plasma renin activity in coarctation of the aorta before and after surgical correction.. Heart, 1978, 40, 1415-1418.	2.9	8
178	Aldosterone Regulation in Primary Aldosteronism: Differences between Adenoma and Bilateral Hyperplasia. Clinical Science and Molecular Medicine Supplement, 1976, 51, 329s-332s.	0.5	10
179	Antihypertensive Effect of Spironolactone in Essential, Renal and Mineralocorticoid Hypertension. Clinical Science and Molecular Medicine Supplement, 1973, 45, 219s-224s.	0.5	5